Paper9303393
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
Krishnarao TV and 1 other. Antimicrob Agents Chemother, 1997. Cited by 84 papers, by iCite.
Cite this record
ConductScience Library. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Papers, record 9303393. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9303393
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
- PubMed
- Publication types
- Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Antifungal Agents | Major topic |
| Candida | Major topic |
| Cryptococcus neoformans | Major topic |
| Fluconazole | Major topic |
| Peptides | Major topic |
| Peptides, Cyclic | Major topic |
| Anidulafungin | |
| Caspofungin | |
| Echinocandins | |
| Lipopeptides | |
| Microbial Sensitivity Tests | |
| Solubility | |
| Solvents |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00388167 | Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection | Background |
Source ClinicalTrials.gov
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8816156 | Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. | Clin Infect Dis | 1996 | https://conductscience.org/library/papers/8816156 | PubMed |
| 2 | 7486919 | Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7486919 | PubMed |
| 3 | 8882665 | Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. | AIDS | 1996 | https://conductscience.org/library/papers/8882665 | PubMed |
| 4 | 9124851 | Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/9124851 | PubMed |
| 5 | 8980776 | In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/8980776 | PubMed |
| 6 | 9021188 | Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9021188 | PubMed |
| 7 | 9078447 | Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. | Diagn Microbiol Infect Dis | 1996 | https://conductscience.org/library/papers/9078447 | PubMed |
| 8 | 9087485 | In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9087485 | PubMed |
| 9 | 984806 | Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. | Antimicrob Agents Chemother | 1976 | https://conductscience.org/library/papers/984806 | PubMed |
| 10 | 646347 | Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/646347 | PubMed |
| 11 | 7416742 | Incidence of polyene-resistant yeasts recovered from clinical specimens. | Antimicrob Agents Chemother | 1980 | https://conductscience.org/library/papers/7416742 | PubMed |
| 12 | 6391370 | Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6391370 | PubMed |
| 13 | 3022641 | Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. | Antimicrob Agents Chemother | 1986 | https://conductscience.org/library/papers/3022641 | PubMed |
| 14 | 3049651 | Multicenter evaluation of four methods of yeast inoculum preparation. | J Clin Microbiol | 1988 | https://conductscience.org/library/papers/3049651 | PubMed |
| 15 | 2751286 | pH and other effects on the antifungal activity of cilofungin (LY121019). | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2751286 | PubMed |
| 16 | 2551215 | In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2551215 | PubMed |
| 17 | 2221863 | Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/2221863 | PubMed |
| 18 | 2279380 | The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients. | Diagn Microbiol Infect Dis | 1990 | https://conductscience.org/library/papers/2279380 | PubMed |
| 19 | 2177750 | Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. | J Clin Microbiol | 1990 | https://conductscience.org/library/papers/2177750 | PubMed |
| 20 | 8257134 | In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8257134 | PubMed |
Cited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41648543 | Mitochondrial cardiolipin sequestration of caspofungin underlies Cryptococcus neoformans inherent resistance and may contribute to cardiotoxicity. | bioRxiv | 2026 | https://conductscience.org/library/papers/41648543 | PubMed |
| 34778489 | Antifungal Susceptibility Testing: A Primer for Clinicians. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/34778489 | PubMed |
| 29376941 | Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery. | J Fungi (Basel) | 2016 | https://conductscience.org/library/papers/29376941 | PubMed |
| 27760359 | Mode of Action of a Designed Antimicrobial Peptide: High Potency against Cryptococcus neoformans. | Biophys J | 2016 | https://conductscience.org/library/papers/27760359 | PubMed |
| 21784998 | Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans. | Eukaryot Cell | 2011 | https://conductscience.org/library/papers/21784998 | PubMed |
| 21646428 | Regulatory circuitry governing fungal development, drug resistance, and disease. | Microbiol Mol Biol Rev | 2011 | https://conductscience.org/library/papers/21646428 | PubMed |
| 19734369 | Chitinases are essential for sexual development but not vegetative growth in Cryptococcus neoformans. | Eukaryot Cell | 2009 | https://conductscience.org/library/papers/19734369 | PubMed |
| 18375617 | Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. | Eukaryot Cell | 2008 | https://conductscience.org/library/papers/18375617 | PubMed |
| 18070978 | Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18070978 | PubMed |
| 17400891 | Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans. | Eukaryot Cell | 2007 | https://conductscience.org/library/papers/17400891 | PubMed |
| 16333416 | Caspofungin: the first agent available in the echinocandin class of antifungals. | Proc (Bayl Univ Med Cent) | 2002 | https://conductscience.org/library/papers/16333416 | PubMed |
| 16304173 | Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/16304173 | PubMed |
| 16304150 | Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/16304150 | PubMed |
| 16278457 | A chitin synthase and its regulator protein are critical for chitosan production and growth of the fungal pathogen Cryptococcus neoformans. | Eukaryot Cell | 2005 | https://conductscience.org/library/papers/16278457 | PubMed |
| 15980360 | Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15980360 | PubMed |
| 15673756 | Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15673756 | PubMed |
| 15643067 | Coccidioides posadasii contains a single 1,3-beta-glucan synthase gene that appears to be essential for growth. | Eukaryot Cell | 2005 | https://conductscience.org/library/papers/15643067 | PubMed |
| 15504857 | Potential for interactions between caspofungin and nelfinavir or rifampin. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/15504857 | PubMed |
| 15297486 | Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. | J Clin Microbiol | 2004 | https://conductscience.org/library/papers/15297486 | PubMed |
| 15105159 | In vitro activity of anidulafungin against selected clinically important mold isolates. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/15105159 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9303393
GET https://conductscience.org/api/papers/v1/9303393/references?page=2